Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Aquinox Pharmaceutic (AQXP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 54,613
  • Shares Outstanding, K 23,540
  • Annual Sales, $ -26,700 K
  • Annual Income, $ 570 K
  • 36-Month Beta -11.44
  • Price/Sales 2.19
  • Price/Cash Flow N/A
  • Price/Book 0.71

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.50
  • Growth Rate Est. (year over year) +199,900.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.00 +16.50%
on 11/14/18
2.51 -7.17%
on 12/06/18
+0.07 (+3.10%)
since 11/12/18
3-Month
2.00 +16.50%
on 11/14/18
3.06 -23.86%
on 09/24/18
-0.52 (-18.25%)
since 09/12/18
52-Week
1.96 +18.88%
on 06/28/18
16.90 -86.21%
on 02/14/18
-7.94 (-77.31%)
since 12/12/17

Most Recent Stories

More News
Aquinox Pharmaceuticals Announces Third Quarter 2018 Financial Results

Aquinox Pharmaceuticals, Inc. ("Aquinox") (NASDAQ:AQXP), a pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, today provided...

AQXP : 2.33 (+0.43%)
X4 Pharmaceuticals Appoints Gary J. Bridger, PhD, to Board of Directors

X4 Pharmaceuticals, a clinical stage biotechnology company developing novel oral CXCR4 antagonists to improve immune cell trafficking to treat rare disease and certain cancers, today...

AQXP : 2.33 (+0.43%)
XENE : 7.22 (+2.41%)
AOM : 36.40 (+0.47%)
Consolidated Research: 2018 Summary Expectations for Aquinox Pharmaceuticals, Xilinx, West Pharmaceutical Services, nVent Electric, World Wrestling Entertainment, and HD Supply -- Fundamental Analysis, Key Performance Indications

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Aquinox Pharmaceuticals,...

WWE : 73.95 (-1.98%)
AQXP : 2.33 (+0.43%)
HDS : 38.14 (-1.42%)
XLNX : 90.54 (+2.73%)
WST : 107.75 (+1.02%)
NVT : 22.84 (+1.24%)
Aquinox and Astellas Announce Exclusive Licensing Agreement for Rosiptor in the Asia-Pacific Region Including Japan

-Aquinox to Receive $25M in Upfront Payment, Potentially Over $100M in Additional Milestone Payments and Royalties-

AQXP : 2.33 (+0.43%)
Aquinox Pharmaceuticals Announces First Quarter 2018 Financial Results

Aquinox Pharmaceuticals, Inc. ("Aquinox") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers,...

AQXP : 2.33 (+0.43%)
Aquinox to Present at Deutsche Bank 43rd Annual Healthcare Conference

Aquinox Pharmaceuticals, Inc. ("Aquinox") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers,...

AQXP : 2.33 (+0.43%)
DB : 9.03 (+8.40%)
Aquinox to Present at 2018 Bloom Burton & Co. Healthcare Conference

Aquinox Pharmaceuticals, Inc. ("Aquinox") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers,...

AQXP : 2.33 (+0.43%)
Aquinox to Present at the 17th Annual Needham Healthcare Conference

Aquinox Pharmaceuticals, Inc. ("Aquinox") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers,...

AQXP : 2.33 (+0.43%)
Aquinox Pharmaceuticals, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 12, 2018 / Aquinox Pharmaceuticals, Inc. (NASDAQ: AQXP) will be discussing their earnings results in their Q4 Earnings Call to be held on March 12, 2018, at 4:30 PM Eastern...

AQXP : 2.33 (+0.43%)
Aquinox Pharmaceuticals to Announce Year End 2017 Financial Results

Aquinox Pharmaceuticals, Inc. ("Aquinox") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers,...

AQXP : 2.33 (+0.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Trade AQXP with:

Business Summary

Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company discovers and develops oral drug candidates to treat inflammation and cancer. Aquinox Pharmaceuticals, Inc. is headquartered in Vancouver, Canada.

See More

Key Turning Points

2nd Resistance Point 2.43
1st Resistance Point 2.38
Last Price 2.33
1st Support Level 2.27
2nd Support Level 2.21

See More

52-Week High 16.90
Fibonacci 61.8% 11.19
Fibonacci 50% 9.43
Fibonacci 38.2% 7.67
Last Price 2.33
52-Week Low 1.96

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar